What helped them develop the vaccine at a record-breaking speed was an innovative artificial intelligence (AI) technology geared toward clearing study data analysis and prediction obstacles. The technology enabled the Pfizer team to review clinical trial data in a mere 22 hours after meeting the primary efficacy case counts. The tool not only saved an entire month that they had not anticipated but also enabled Pfizer to maintain a high level of data quality throughout the trial.
The revolutionary technology was Smart Data Query (SDQ) in the Life Science Analytics Cloud (LSAC) platform from Saama Technologies, the AI-driven Intelligent Clinical Cloud company that enables the life sciences industry to conduct faster and safer clinical development and regulatory programs.
“Through SDQ, LSAC was able to process up to 200 million clinical data points per day, cleansing the data as it appeared from patients around the world. As a single, unified data aggregation and analytics platform, Saama’s LSAC is designed to allow drug development teams—including clinical operations, medical, and data management—to make more informed decisions,” says Suresh Katta, CEO, Saama Technologies. The company enables pharma companies in bringing their drugs to the market faster.
At its core, LSAC is an AI platform that implements smart algorithms that can connect with all types of data sources. The platform can then quickly contextualize the data, enabling clients to save several hours rather than waste time manually cleaning the data which is highly error-prone. Finally, LSAC turns the contextualized connected data into conversational data, which can communicate with all types of devices to gain insights.
With all the data in one place, clients can ensure security, scalability, and quality across the drug development lifecycle
The platform brings client’s heterogeneous data—from EDC, CTMS, financials, ePRO, IVRS, central/local labs, multiomics, biomarkers, real-world data—together into a unified model that accelerates clinical development outcomes. The data aggregation is agnostic to source, structure, and existing infrastructure. “With all the data in one place, clients can ensure security, scalability, and quality across the drug development lifecycle, while gaining workflow efficiencies such as automated alerts, a collaborative task management system, and AI-powered predictive analytics and search,” says Katta. By offering oversight across more than 1,500 clinical studies, LSAC has become the platform of choice for more than 50 biopharmaceutical companies worldwide.
Rather than replacing the client’s existing IT infrastructure, Saama’s LSAC works to enhance the systems. Since LSAC is compatible with all IT and data infrastructure, Saama can easily serve the needs of a wide variety of clients. “We cover everything including cloud and hybrid infrastructures; we also help clients in their journey from traditional relational databases all the way to Snowflake and other technologies,” adds Katta. In addition, the technology's impeccable implementation speed adds a silver lining to LSAC. Rather than bringing large implementation teams that take months to deploy the technology, Saama’s LSAC can be configured in a few days to weeks.
With such exemplary features, Saama is all set to equip the pharma industry to leverage the maximum benefits of AI technology. “Till now, modern medicine has only been able to introduce therapies for less than 10 percent of known illnesses in the human body because it is extremely costly to develop them. We want to enable pharma companies to build a smart platform for cost-effective clinical development processes,” says Katta. The company also aims to bring the ability to intelligently share research across the industry to further augment and fast-track the drug development process.
Saama Technologies News
Biopharma Industry LeadersIan Read and Clive Meanwell Join Saama Board of Directors
CAMPBELL, CA - Saama Technologies, Inc. (“Saama”) today announced the appointment of six individuals to its Board of Directors.
Saama board members now include:
• Suresh Katta, Founder and CEO of Saama
• Ian Read, former CEO and Executive Chairman of Pfizer
• Clive Meanwell, Founder and former CEO of The Medicines Company
• Steve Wise, Head of Global Healthcare, Carlyle
• Joe Bress, Managing Director, Carlyle
• Ashley Evans, Managing Director, Carlyle
• Andrea Jackson, Director, Northpond Ventures
This announcement follows the recent strategic investment in Saama of up to $430M by Carlyle and co-investors, including Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund (“Merck GHI”), McKesson Ventures, Northpond Ventures, Pfizer Ventures, and Population Health Partners.
“I am looking forward to the opportunity to help Saama architect and advance the future of clinical development and the life sciences industry,” said Ian Read. “It’s an honor to join Saama’s Board of Directors and the industry experts who comprise it.”
“It’s exciting to join Saama’s team in their mission of empowering pharmaceutical and biotechnology companies to bring better medical treatments to market faster, more efficiently, and with ever-greater validity,” said Clive Meanwell.
“With our landmark strategic investment fully closed, Saama is doubling down onits efforts to empower all pharmaceutical and biotechnology companies to redefine and accelerate their drug development paradigms and regulatory submission processes through the democratized use of AI-driven analytics solutions and platforms,” said Suresh Katta. “Saama and the entire life sciences industry is poised for growth in this excitingnew era of clinical development, and the addition of Ian and Clive to our Board will enable us to have an even greater impact than ever before.”
Ian Read joined Pfizer in 1978. Prior to his tenure as CEO, Ian served as Senior Vice President and Group President of Pfizer’s Worldwide Biopharmaceutical Businesses, overseeing five global business units: Primary Care, Specialty Care, Oncology, Established Products, and Emerging Markets. He also held positions in several of the company’s largest, fastest-growing operations, including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil.
Clive Meanwell is Executive Chairman of Population Health Partners LLC, a global investment firm, and Chief Executive Officer of Population Health Investment Corporation, a special purpose acquisition company. In 1996, Dr. Meanwell founded biopharmaceutical company The Medicines Company. He served as a member of the Board of Directors and held a range of leadership positions including Chairman, Executive Chairman, Chief Executive, and Chief Innovation Officer until January 6, 2020, when Novartis AG acquired the company.